Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.
Nakasone
H
H
Kanda
Y
Y
Takasaki
H
H
Nakaseko
C
C
Sakura
T
T
Fujisawa
S
S
Yokota
A
A
Yano
S
S
Usuki
K
K
Maruta
A
A
Abe
D
D
Hoshino
T
T
Takahashi
S
S
Kanamori
H
H
Okamoto
S
S
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D020544:Graft vs Leukemia Effect / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate